Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and mass balance study of [14C]-vafidemstat in healthy male participants
NL-OMON61095Phase 1Completed
- Sponsor
- Oryzon Genomics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vafidemstat, sponsored by Oryzon Genomics. Primary endpoint: Primary endpoint(s). Started Jun 2026; status: completed.
02
Drugs
vafidemstat
Beyond the preview
Go deeper on NL-OMON61095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61095.